Loss of miR-342-3p expression and over-expression of MCT1 among tumor cells in TNBC contribute to the establishment of important pathways in tumor biology, thus these alterations open new possible therapeutics strategies for MCT1 inhibition that might have clinical implications. This evidence concerns the gene SLC16A1 and neoplasm.